NewCardio(OTC) NWCI

NewCardio, Inc. is a cardiac diagnostic technology provider, which focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular diseases, as well as the cardiac safety assessment of drugs under development. It engages in the development of three solutions through a 3D platform technology, which includes, QTinno, an automated cardiac safety solution that streamlines the process for meeting the early phase cardiac safety analysis, CardioBip, a wireless transtelephonic system which engages in delivering remote diagnosis and review of patients with chronic cardiac conditions, and my3KG, a software application developed to assess cardiac electrical activity in time and space. The company was founded on September 2, 2003 and is headquartered in Princeton, NJ.